Matthew Hebden Porteus is Sutardja Chuk Professor of Definitive and Curative Medicine at Stanford University.[1] In 2003, as a postdoctoral fellow in David Baltimore's lab at the California Institute of Technology, Porteus was the first to demonstrate precise gene editing in human cells using chimeric nucleases.[2]
Matthew Porteus | |
---|---|
Alma mater | Harvard University Stanford University |
Scientific career | |
Institutions | Stanford University California Institute of Technology Massachusetts Institute of Technology |
Thesis | Isolation and Characterization of TES-1/DLX-2: A Novel Homeobox Gene Expressed During Mammalian Forebrain Development (1994) |
He graduated magna cum laude from Harvard University and completed his MD and PhD at Stanford University.[3] For his post-doctoral work he trained with David Baltimore at MIT and Caltech.[3] He is a scientific founder of CRISPR Therapeutics and an academic founder of Graphite Bio.[4][5]
He has an h-index of 69 according to Google Scholar.[6]